Rheumatology (Oxford) 2012;51:552556
We know these drugs represent a massive breakthrough in our long fight against obesity-related clinical conditions, but their high cost has been the subject of substantial debate, said David Kim, PhD, a UChicago health economist
This section discusses what drives the cost, how price might influence access, and what support options patients could have
The CagriSema combination (cagrilintide plus semaglutide) has received more clinical attention, with Novo Nordisk advancing this combination through Phase 3 trials
Larger meals trigger more GLP-1 release, but frequent smaller meals may sustain elevated levels throughout the day
Researchers working in the gut health and metabolic space are particularly interested in how the triple-agonist approach affects liver-gut axis signaling